Novartis AG has experienced a significant increase in its U.S. shares, reaching near year-high levels before the company's earnings are released. Multiple large companies, including Lockheed Martin Investment Management Co., Boston Common Asset Management LLC, and Wealth Enhancement Advisory Services LLC, have shown steady investment interest. Despite some shares falling due to generic competition affecting its heart drug market, the stock has benefited from substantial multi-year share price gains. Novartis has further boosted its growth prospects through its recent breakthrough treatment for Sjogren's Disease and U.S. manufacturing expansions aiming to mitigate tariff exposure. Despite Goldman Sachs claiming the stock as overvalued, there are other promising partnership advancements such as the acquisition of Regulus Therapeutics. However, some investors express concern about Novartis's valuation after strong recent shareholder returns and overvaluation. Notably, Novartis's CEO has stated the company is likely protected from U.S. tariffs, a factor contributing to the stock's continued bullish run.
Novartis Stocks News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Sat, 24 Jan 2026 20:30:10 GMT -
Rating 7
- Innovation 5
- Information 7
- Rumor -5
